



FINANCIAL TEAR SHEET

Corporate Profile


Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce’s technology also looks to match and deliver the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as the knowledge acquired from Jounce’s Translational Science Platform, to create a sustainable pipeline that makes a difference in the lives of cancer patients.

Stock Information

JNCE (COMMON STOCK)

Exchange	NASDAQ GS (US Dollar)
Price	\$18.37
Change (%)	▼ 0.39 (2.08%)
Volume	208,511
52 Week Low	\$11.05
Market Cap	\$607,665,122
Rolling EPS	-0.54
PE Ratio	0
Shares Outstanding	32,391,531

Data as of 04/24/18 4:00 p.m. ET



Recent Headlines & Events

04/12/18 - 8:00 a.m.

Jounce Therapeutics to Present Nonclinical Translational Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting

There are currently no events scheduled.

03/08/18 - 6:30 a.m.

Jounce Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

03/05/18 - 8:01 a.m.

Jounce Therapeutics to Present at Cowen and Company 38th Annual Health Care Conference

SEC Filings

FILING DATE	FORM
04/09/18	S-3/A
03/19/18	4
03/12/18	4
03/12/18	4

Data provided by NASDAQ. Stock information is delayed a minimum of 15 minutes.